Jill Desimone Biography and Net Worth

Jill DeSimone has served as a member of our board of directors since May 2022. Ms. DeSimone served as President of U.S. Oncology at Merck & Co., Inc. from 2014 to May 2022. During her time at Merck, Ms. DeSimone also temporarily served as Interim President of U.S. Pharma to help navigate the business through the COVID-19 pandemic. Prior to joining Merck, she served as Senior Vice President of Global Women’s Health at Teva Pharmaceutical Industries Ltd from 2012 to 2014. Prior to her time at Teva, Ms. DeSimone served in several roles of increasing responsibility at Bristol Myers Squibb from 1980 to 2012, including Senior Vice President of U.S. Commercial from 2010 to 2012 and Senior Vice President of U.S. Virology/HIV from 2006 to 2010. Ms. DeSimone serves as a board member for the Florida Cancer Specialists Foundation, a nonprofit organization that helps individuals with their essential living expenses while they undergo treatment for cancer. Ms. DeSimone received a B.S. in pharmacy from Northeastern University and completed a fellowship with the Wharton School of the University of Pennsylvania.

What is Jill Desimone's net worth?: The estimated net worth of Jill Desimone is at least $35,838.60 as of October 5th, 2023. Desimone owns 966 shares of Praxis Precision Medicines stock worth more than $35,839 as of May 14th. This net worth evaluation does not reflect any other investments that Desimone may own. Learn More about Jill Desimone's net worth.
How do I contact Jill Desimone?: The corporate mailing address for Desimone and other Praxis Precision Medicines executives is 101 MAIN STREET #1210, CAMBRIDGE MA, 02142. Praxis Precision Medicines can also be reached via phone at 617-300-8460 and via email at investors@praxismedicines.com. Learn More on Jill Desimone's contact information.
Has Jill Desimone been buying or selling shares of Praxis Precision Medicines?: Jill Desimone has not been actively trading shares of Praxis Precision Medicines within the last three months. Most recently, on Thursday, October 5th, Jill Desimone bought 966 shares of Praxis Precision Medicines stock. The stock was acquired at an average cost of $26.25 per share, with a total value of $25,357.50. Following the completion of the transaction, the director now directly owns 966 shares of the company's stock, valued at $25,357.50. Learn More on Jill Desimone's trading history.
Who are Praxis Precision Medicines' active insiders?: Praxis Precision Medicines' insider roster includes Jill Desimone (Director), Lauren Mastrocola (Insider), Alex Nemiroff (General Counsel), and Marcio Souza (CEO). Learn More on Praxis Precision Medicines' active insiders.
Are insiders buying or selling shares of Praxis Precision Medicines?: In the last twelve months, insiders at the sold shares 2 times. They sold a total of 13,427 shares worth more than $1,085,042.44. The most recent insider tranaction occured on November, 14th when General Counsel Alex Nemiroff sold 8,239 shares worth more than $660,767.80. Insiders at Praxis Precision Medicines own 2.7% of the company. Learn More about insider trades at Praxis Precision Medicines.
Information on this page was last updated on 11/14/2024.

Jill Desimone Insider Trading History at Praxis Precision Medicines

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/5/2023	Buy	966	$26.25	$25,357.50	966

Jill Desimone Buying and Selling Activity at Praxis Precision Medicines

Praxis Precision Medicines Company Overview

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Today's Range

Now: $37.10

$35.41

$37.96

50 Day Range

MA: $35.62

$28.47

$40.24

2 Week Range

Now: $37.10

$26.70

$91.83

Volume

277,328 shs

Average Volume

489,638 shs

Market Capitalization

$755.69 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.65